Treatment of patients with acute promyelocytic leukemia using AIDA regiments: 20-year single-center experience
Medicinska istrazivanja · 2025
DOI: 10.5937/medi0-56551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicinska istrazivanja, 2025. Verfasst von Mirjana Mitrović und 20 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The introduction of all-trans retinoic acid (ATRA) has transformed acute promylocitic leucaemia (APL) from a highly fatal to a curable disease. However, significant frequency of early death (ED) and relapse represent challenges in everyday practice. The aims of this study are to report our 20 years long experience using AIDA-based protocols and to assess the predictive value of clinical and laboratory parameters for ED/relapse development. Material and methods: This retrospective study included patients treated at the Clinic for Hematology, UKCS in the period 2004-2024. RS was defined as death within the first 30 days of hospitalization.
Results
158 patients were included. ED and relapse occurred in 38/158 (24%) and 15/119 (12.6%) patients. ED rate stayed stable through time (2004-2008 period 20.6%, 2009-2013 21.9%, 2014-2018 23.1%, 2019-2024 27%) with bleeding as the most frequent cause (42%), followed by DS (24%) and infection (16%). Final predictors for ED development were ISTH DIC score (p=0.008, OR 2.38, 95% CI 1.25-4.53), aPTT (p=0.009, OR 0.79, 95% CI 0.66-0.94), ECOG PS (p<0.001, OR 2.96, 95% CI 1.63-5.39). Predictors for relapse were: ECOG PS ≥ 3 (21.7% vs 78.3%, p=0.019) and bcr3 PML-RARA transcript (29.6% vs 70.4%, p=0.046).
Conclusion
Our experience showed a very high rate of ED, with haemorrhage, DS and infection as a main reason. Preventive strategies should include comprehensive medical education, regarding prompt recognition, appropriate early transfusion support therapy, and the rapid initiation of ATRA. Patients with high ECOG PS and ISTH DIC score probably need different coagulation monitoring and reinvented therapy.
Zitieren
APA
Mitrović, M., Sabljić, N., Pantić, N., Trajković, L., Bukumirić, Z., Virijević, M., Pravdić, Z., Jaković, L., Jovanović, J., Kraguljac-Kurtović, N., Milosević, V., Rajić, J., Cvetković, M., Đorđević, V., Knezević, V., Dragović-Ivančević, T., Bižić-Radulović, S., Tošić, N., Vidović, A., …, & Suvajdžić-Vuković, N. (2025). Treatment of patients with acute promyelocytic leukemia using AIDA regiments: 20-year single-center experience. Medicinska istrazivanja. https://doi.org/10.5937/medi0-56551
Vancouver
Mitrović M, Sabljić N, Pantić N, Trajković L, Bukumirić Z, Virijević M, et al. Treatment of patients with acute promyelocytic leukemia using AIDA regiments: 20-year single-center experience. Medicinska istrazivanja. 2025. doi:10.5937/medi0-56551
BibTeX
@article{Mitrovi2025,
author = {Mitrović, Mirjana and Sabljić, Nikica and Pantić, Nikola and Trajković, Lazar and Bukumirić, Zoran and Virijević, Marijana and Pravdić, Zlatko and Jaković, Ljubomir and Jovanović, Jelica and Kraguljac-Kurtović, Nada and Milosević, Violeta and Rajić, Jovan and Cvetković, Mirjana and Đorđević, Vesna and Knezević, Vesna and Dragović-Ivančević, Tijana and Bižić-Radulović, Sandra and Tošić, Nataša and Vidović, Ana and Bogdanović, Andrija and Suvajdžić-Vuković, Nada},
title = {Treatment of patients with acute promyelocytic leukemia using AIDA regiments: 20-year single-center experience},
journal = {Medicinska istrazivanja},
year = {2025},
doi = {10.5937/medi0-56551}
}
EUVIMED